The American Cancer Society now recommends clearer PSA screening schedules, with earlier annual testing for Black men and certain men with a family history, following stronger evidence that screening can reduce prostate cancer deaths.
Sunharbo reduced ischemic stroke risk by 26% in a phase 3 trial, but bleeding concerns affected some patients. Cardiologist Richard Kovacs says treatment discussions should begin soon after a qualifying stroke because trial participants received the drug within 72 hours.
Stopping GLP-1 treatment can revive cravings, drive weight regain, worsen metabolic markers and compound muscle loss concerns. Dr. Frank Dumont says durable nutrition changes and medical guidance are crucial for patients considering discontinuation.
Linda Gilbert alleges a medication substitution during knee replacement surgery caused permanent spinal cord damage and left her unable to walk. Her lawsuit seeks $150 million as the hospital reviews corrective actions following an error affecting four patients.
Teen boys are reportedly experimenting with erdafitinib after online discussions promoted its possible effects on height, but physicians warn the cancer medication can cause permanent vision damage, metabolic abnormalities and severe skeletal complications.
A randomized trial of 1,880 adults aged 70 and older found a higher rate of heart attack, ischemic stroke or death among those assigned to stop statins, while quality of life and muscle outcomes showed no meaningful differences.
The FDA is requiring updated warnings for several popular GLP-1 medicines after reviewing evidence of a potential increased risk of NAION, a serious condition that can cause sudden vision loss and permanent sight impairment.
More than 3,700 bottles of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets are being recalled nationwide after a component failed dissolution testing requirements, prompting a Class II designation from federal regulators.